• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002727.SZ
Share

Yixintang Pharmaceutical Group Co., Ltd. Stocks

CN¥ 11Last Updated 15.07.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 874.61M

CN¥ 11
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yixintang Pharmaceutical Group Co., Ltd. is a prominent Chinese enterprise primarily managing an extensive network of pharmacies nationwide. The company's operations also encompass the production and retail of a diverse array of items, including raw medicinal ingredients, traditional Chinese herbal medicines, and various health and dietary supplements. Furthermore, it actively participates in pharmaceutical distribution. By January 31, 2020, its retail footprint spanned 7,205 outlets across numerous provinces and municipalities, such as Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, and Qiong. Complementing its brick-and-mortar presence, Yixintang also conducts online sales. Established in 2000 with its headquarters in Kunming, China, the company adopted its current name, Yixintang Pharmaceutical Group Co., Ltd., in June 2019, having previously been called Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, underva

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 002727.SZ is 15.5 and suggests 49.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 19:54

Sales at Cartier's parent company were twice as strong as expected. This bolstered the luxury market

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Chip test maker Aehr extending gains after earnings and revenue beats, upbeat outlook

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026